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Abstract
Background: Human pluripotent stem cells have the ability to generate all cell types present in the adult organism,
therefore harboring great potential for the in vitro study of differentiation and for the development of cell-based therapies.
Nonetheless their use may prove challenging as incomplete differentiation of these cells might lead to tumoregenicity.
Interestingly, many cancer types have been reported to display metabolic modifications with features that might be similar
to stem cells. Understanding the metabolic properties of human pluripotent stem cells when compared to their
differentiated counterparts can thus be of crucial importance. Furthermore recent data has stressed distinct features of
different human pluripotent cells lines, namely when comparing embryo-derived human embryonic stem cells (hESCs) and
induced pluripotent stem cells (IPSCs) reprogrammed from somatic cells.
Methodology/Principal Findings: We compared the energy metabolism of hESCs, IPSCs, and their somatic counterparts.
Focusing on mitochondria, we tracked organelle localization and morphology. Furthermore we performed gene expression
analysis of several pathways related to the glucose metabolism, including glycolysis, the pentose phosphate pathway and
the tricarboxylic acid (TCA) cycle. In addition we determined oxygen consumption rates (OCR) using a metabolic
extracellular flux analyzer, as well as total intracellular ATP levels by high performance liquid chromatography (HPLC). Finally
we explored the expression of key proteins involved in the regulation of glucose metabolism.
Conclusions/Findings: Our results demonstrate that, although the metabolic signature of IPSCs is not identical to that of
hESCs, nonetheless they cluster with hESCs rather than with their somatic counterparts. ATP levels, lactate production and
OCR revealed that human pluripotent cells rely mostly on glycolysis to meet their energy demands. Furthermore, our work
points to some of the strategies which human pluripotent stem cells may use to maintain high glycolytic rates, such as high
levels of hexokinase II and inactive pyruvate dehydrogenase (PDH).
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Introduction
Human embryonic stem cells (hESCs) are self-renewing and
pluripotent cells derived from the inner cell mass (ICM) of a
blastocyst prior to implantation. However, although they can be
differentiated into any somatic cell lineage, they cannot be
genetically matched to putative patients in possible cell replace-
ment therapies. However, it has been recently shown that human
somatic cells can be reprogrammed into hESC-like pluripotent
stem cells, the so called induced pluripotent stem cells (IPSCs), by
the ectopic expression of a combination of pluripotency factors
and using a variety of approaches [1,2,3]. The differences and
similarities of hESCs and IPSCs have been studied at several
levels, namely differentiation potential, global gene expression,
and epigenetic status. The various analyses have revealed that
despite the high level of resemblance in terms of pluripotency these
cell types are not identical [4,5,6,7,8]. Namely, gene expression
profiling revealed that, while IPSCs are highly similar to ESCs, a
unique gene expression signature appears in IPSCs regardless of
their origin [4]. Furthermore, DNA methylation analysis revealed
that the methylome of certain developmental genes in IPSCs was
intermediate between that found in differentiated cells and ESCs.
In other cases, the methylation pattern in IPSCs was exclusive,
differing from both ESCs and differentiated cells [6] , suggesting
both the occurrence of abnormal methylation during reprogram-
ming and that some ‘‘epigenetic memory’’ from the somatic cells
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reprogrammed may linger in IPSCs, with unknown consequences
[9], although the extent of this phenomenon is questioned [10].
Recent data suggests that IPSCs may be more prone to genetic
mutation and instability [11,12,13]. Recently, Zhao et al. [14]
demonstrated immunogenicity differences between authentic
ESCs and iPSCs. Given the potential of these cells, further studies
are needed to scrutinize these differences and to understand their
impact on differentiation potential and possible therapeutic
applications.
The mammalian embryo resides in a hypoxic environment
prior to implantation [12]. During the early stages of embryonic
development there is a metabolic shift from oxidative phosphor-
ylation (OXPHOS) to glycolysis, and oxidative metabolism is only
fully reinstituted after implantation [15]. Studies in the mouse and
hamster indicated that the number of mitochondria is higher in
the trophectoderm (TE) than in the ICM. Furthermore, the ICM
is characterized by spherical and depolarized mitochondria with
low O2 consumption, whereas mitochondria of the TE are
elongated and have both higher mitochondrial potential and
higher O2 consumption [16,17,18].
Similarly to ICM cells, embryonic stem cells rely mostly on
glycolysis for energy supply. Furthermore, the mitochondria in
these cells are rather immature with perinuclear localization. As
human pluripotent stem cells differentiate they acquire more
mature mitochondria and undergo a metabolic switch from
glycolysis to OXPHOS [16,19,20,21]. In agreement with these
findings several authors have reported that hypoxia is beneficial
for the maintenance of hESCs in a pluripotent state [22,23]. In
addition low O2 tensions have been reported to increase the
reprogramming efficiency of both mouse and human somatic cells
[24].
It is known that glycolysis and OXPHOS function in a
coordinated fashion, and that the former generates 18 times more
ATP per molecule of oxidized glucose than the former [25]. The
first glycolytic reaction is crucial as glucose is captured within the
cell by conversion to glucose 6-phosphate. This is one of the rate
limiting steps in glycolysis and is catalyzed by hexokinases. Cell
types with high glycolytic rates have been reported to have high
expression levels of hexokinases [26,27]. Glucose 6-phosphate can
be further metabolized in glycolysis producing two molecules of
pyruvate, NADH and ATP. In normoxic conditions pyruvate
enters mitochondria and links glycolysis to aerobic respiration by
entering the TCA cycle (which provides the mitochondrial
electron transfer chain (ETC) with reducing agents for ATP
synthesis) as acetyl-coenzyme A. However under low O2 tensions
or in the presence of dysfunctional mitochondria pyruvate will be
converted to lactate.
The pyruvate dehydrogenase (PDH) complex, localized in the
mitochondrial matrix is the link between glycolysis and the TCA
cycle. It is composed of several copies of three catalytic proteins
(E1, E2 and E3) that catalyze the irreversible decarboxylation of
pyruvate to acetyl-coenzyme A and NADH [28,29]. The E1-alpha
subunit is considered the on/off switch of the PDH complex, as its
phosphorylation by one of the four pyruvate dehydrogenase kinase
isoforms (PDHK1-4) leads to PDH complex inactivation, whereas
removal of one phosphate group by one of the two pyruvate
dehydrogenase phosphatases (PDP1 and PDP2) activates the
complex [28,29]
The exact mechanism by which hESCs maintain an anaerobic
metabolism even in the presence of oxygen remains largely elusive.
However, there is certain putative parallelism with what has been
described for cancer cells, which also maintain glycolysis as a key
metabolic pathway under normoxia, in detriment to OXPHOS,
the so-called Warburg effect [30]. Furthermore it has been
recently shown that some cancer lines cultured under hypoxia
acquire an undifferentiated phenotype similar to that of ESCs
[31]. The aerobic glycolysis feature of cancer cells may involve the
regulation of PDH function, at least in some cases, and indeed
modulation of PDH function has been therapeutically considered
in cancer [32]. However these analogies must be considered with
great care, as there are considerable metabolic variations between
cancer cell lines [33,34].
Additionally, it would be of interest to determine if and how
IPSCs acquire a more glycolytic metabolism upon reprogram-
ming, or if they instead maintain the metabolic features of the
original somatic cell type that was reprogrammed. In this study
our aim was to answer these questions by further characterizing
the energy metabolism of both hESCs and human IPSCs when
compared with their differentiated somatic counterparts. Towards
that goal we analyzed mitochondrial morphology, glucose-related
gene expression, OCR, intracellular ATP levels, lactate produc-
tion and protein levels of regulatory enzymes relevant in
metabolism.
In accordance to previous reports our results demonstrate that
hESCs have mitochondria consistent with lower activity, at least
when compared to differentiated cells. Furthermore we show that
mitochondria in IPSCs are morphologically distinct from both
hESC and differentiated somatic cell mitochondria. In addition
IPSCs are not identical to hESCs in terms of glucose-related gene
expression, although they cluster with hESCs rather than with
their somatic counterparts. Moreover analysis of OCR, intracel-
lular ATP and lactate levels confirm that human pluripotent stem
cells rely mostly on glycolysis to meet their energy demands.
Finally our study demonstrates that human pluripotent stem cells
express high levels of hexokinase II and have an inactive PDH
complex. In all parameters quantified IPSCs seem to be close to
hESC, but at slightly lower levels of expression/activity. These
results shed light on some of the mechanisms that human
pluripotent cells use to maintain high levels of glycolysis under
normoxia.
Materials and Methods
Cell culture
In this work we used hESC lines WA07, WA09 and WA01
(WiCell Research Institute, Madison, WI), human IPSC lines
HFF1 iPS, IMR-90 iPS (WiCell Research Institute) and AE iPS
(derived in our laboratory). In terms of differentiated fibroblasts,
both the IMR-90 human diploid fibroblast and the human
foreskin fibroblast (HFF1) strains were obtained from American
Type Culture Collection (ATTC, Manassas, VA); these lines were
reprogrammed to form the IMR-90 iPS and HFF1 iPS lines noted
above, respectively. Finally, differentiated H7TF fibroblasts were
isolated from a WA07 ESC-derived teratoma, following injection
of WA07 hESCs into immunocompromised mice.
HESC and IPSC lines were cultured in mTeSRTM (STEM-
CELL Technologies, Vancouver, BC, Canada) on matrigel (BD
Biosciences; San Jose, CA) coated dishes. Both H7TF and HFF1
were cultured in CF1 medium containing: 90% Dulbecco’s
Modified Eagle’s medium; 10% fetal bovine serum (FBS); 1%
MEM non-essential amino acids; 1% penicillin/streptomycin
(Pen/Strep) and 1% 2 mM L-glutamine (all from Invitrogen,
Carlsbad, CA). The IMR-90 line was cultured in 90% Eagle’s
minimal essential medium (ATTC, Manassas, VA), 10% FBS and
1% Pen/Strep. All lines were maintained at 37uC, 21% O2 and
5% CO2. Throughout the work WA07, IMR-90 iPS, H7TF and
IMR-90 lines were used in the majority of the experiments in
order to compare cell lines that have the same genetic background.
Energy Metabolism in Pluripotent Cells
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20914
The other lines were used in key experiments to consolidate the
results trying to avoid any artifact that could be line specific or
culture derived.
Transduction of pluripotent and differentiated cells using
a baculovirus system
Mitochondria GFP labeling was performed using the organelle
lights Mito reagent (CellLightTM Mitochondria-GFP by Molecular
Probes/Invitrogen). This system is a baculovirus system that
contains a leader sequence for the E1 alpha pyruvate dehydro-
genase fused with GFP protein. Cells were plate on coverslips and
cultured for three days or 24 hours, for pluripotent and
differentiated cells, respectively. Cells were rinsed with PBS, and
incubated in PBS containing 82% organelle lights reagent during
30 minutes at room temperature with gentle shaking. Organelle
lights mixture was removed and cells were incubated with
appropriated media containing 0.1% enhancer solution (provided)
for two hours at 37uC. Enhancer solution was removed and
replaced by cell culture media. Although the transfection
efficiencies were low, 20 hours later, GFP protein could be
observed in the mitochondria. Cells were then fixed with 4%
paraformaldehyde (Sigma-Aldrich) and imaged using a TCS-SP@
laser scanning confocal microscope (Leica, Microsystems, Gmbh,
Wetzlar, Germany).
Electron Microscopy
Cells were cultured on matrigel or matrix free conditions for
pluripotent cells or differentiated cells, respectively. Cells were
rinsed with PBS and fixed with 2.5 % glutaraldehyde in PBS,
pH 7.4, for 1 hour at room temperature. The fixative was
removed and samples were washed 3 times with PBS at room
temperature for 10 minutes each. Samples were post-fixed for
1 hour at 4uC in 1% osmium tetroxide with 1% potassium
ferricyanide, followed by three washes with PBS (10 minutes each).
Afterwards, samples were dehydrated using a graded ethanol series
(30%, 50%, 70%, and 90%-10 minutes) with three changes in
100% ethanol (15 minutes each). Samples were then incubated
three times with a 100% Epon solution (1 hour each). Finally,
samples were incubated for 1 hour with Epon solution, maintained
overnight at 37uC and afterwards at 60uC for 2 days. Sections
were made using an ultra microtome and imaged in a 1011 CX
Transmission electron microscope (JEOL, Tokyo, Japan).
RNA extraction, DNA clean up and Glucose RT2 profiler
PCR array
Total RNA isolation using the TRIzol reagent (Invitrogen) and
genomic DNA was eliminated with DNA-free kit (Ambion, Austin,
TX) as previously described [35]. An additional step of DNA clean
up was performed using the genomic elimination kit from
SABiosciences (Frederick, MD). In brief, 1 mg of RNA was
incubated with genomic DNA elimination mixture (containing
2 ml of 5X genomic DNA elimination buffer and nuclease free
water) for 5 minutes at 42uC. The first cDNA strand was
synthesized by incubating the product of the genomic DNA
elimination reaction with 10 ml of the Reverse transcriptase (RT)
mixture (5 x reverse transcriptase (RT) buffer, RT, primers and
external control, and nuclease free water) for 15 minutes at 42uC.
Reactions were immediately stopped by heating at 95uC for 5
minutes. RT products were further diluted with 91 ml of nuclease
free water. cDNA samples were then loaded in the glucose gene
expression panel (SABiosciences), run in a 7900HT Real Time
system (Applied Biosystems, Foster City, CA) accordingly to the
following thermal cycle conditions; 95uC for 10 minutes, and 40
cycles at 95uC for 15 seconds and 60uC for one minute. Each
array contained wells that allowed us to control for genomic DNA
contamination, and first cDNA synthesis efficacy. Twelve genes
(ALDO B, FBP1, FBP2, G6PC, GCK, GYS2, HK3, PCK1, PDK4,
PGK2, PKLR and PRPS1L1) were not considered in the analysis, as
their Ct value was above 30. Gene expression differences were
calculated using the -DDCt method. Gene expression was
normalized to the housekeeping gene b-actin and fold change
was calculated relative to the hESC line WA07. p values were
determined using online software provided by SABiosciences.
High Performance liquid Chromatography (HPLC)
Pluripotent cells were cultured as mentioned above for seven
days, whereas differentiated cells were cultured for two days. Cells
were enzymatically dissociated with Accutase (Millipore) or TripLe
Express (Sigma-Aldrich, St. Louis, MO) for pluripotent cells and
differentiated cells, respectively. Adenosine triphosphate (ATP)
was extracted with 0.6 M perchloric acid (Sigma) supplemented
with 25 mM EDTA-Na (Sigma) followed by centrifugation.
Supernatants were neutralized with 3M potassium hydroxide in
1.5M Tris. ATP separated by HPLC. The detection wavelength
was 260 nm and the column was a Licrosphere 100 RP108 5 mm
(Merck). The elution buffer for was 100 mM phosphate buffer
(pH 6.5) supplemented with 1% methanol. Standard for ATP was
purchased from Sigma- Aldrich.
Lactate Production
Lactate levels were determined using the Lactate assay kit
(Biovision). In this assay lactate is enzymatically oxidized and the
product of this reaction reacts with a lactate probe (provided) and
emits fluorescence at Ex/Em=535/587 nm. Both pluripotent and
differentiated cells were plated and cultured for 48 hours. At this
point, fresh media was added to the cells. Twenty-four hours later,
500 ml of medium was collected, and cell numbers were
determined. Medium samples were processed following manufac-
turer’s instructions. Fluorescence was determined using a micro-
plate reader (Spectra Max M2; Molecular Devices, Sunnyvale,
CA). Lactate concentrations were normalized to cell number.
Western blotting
Cells were maintained on matrigel or matrix free conditions for
pluripotent cells or fibroblasts, respectively. Pluripotent cells were
dissociated using Accutase (Millipore), whereas for differentiated
cells Triple E (Sigma-Aldrich) was used. Total cell extracts were
lysed in RIPA buffer (Sigma) supplemented with 1 mM phenyl-
methylsulphonyl fluoride (Sigma-Aldrich) PMSF and 2x Halt
phosphatase inhibitor cocktail (Pierce, Rockford, IL). Mitochon-
drial extracts were isolated using mitochondria isolation kit
(Sigma-Aldrich), as previously described by Wieckowski and
colleagues [36]. In brief, cells were washed once with PBS, and
incubated on ice with the extraction buffer supplemented with cell
lysis detergent (1:200) and PMSF (1:200) for 5 minutes. Samples
were resuspended every minute. Afterwards, we added 2v/v of
extraction buffer and centrifuged twice, at 4uC, for 10 minutes, at
2000 g. Pellets containing the cytosolic fraction were stored at
280uC. Supernatants were transferred to a new tube and
centrifuged, at 4uC for 10 minutes, at 11000 g. Supernatants
were discarded and the pellets containing the mitochondrial
fraction, were washed with extraction buffer, and centrifuged at
4uC, for 20 minutes, at 11000 g. The debris fraction (supernatant)
was stored, as well as, the mitochondrial fraction at 280uC.
Protein quantification was carried out using the Bradford assay
(Bio-Rad laboratories, Inc., CA) and 7 mg of protein were
separated in 4%–15% SDS Page gels (Bio-Rad laboratories).
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The primary antibodies used were: anti - Oxphos complex kit
(1:500, Invitrogen); anti-PDH (1:500, Cell Signaling and Tech-
nologies); anti- PDHK1(1:500, Cell Signaling and Technologies);
anti- phospho PDH-E1a Ser 293 (1:250, EMD); anti-hexokinase II
(1:500, Cell Signaling and Technologies), and anti-Nanog ( 1:500,
Kamiya Biomedical Company, Seattle, WA), ECL Advanced
Western Blot Detection kit (Amersham Biosciences, Piscataway,
NJ) was used for detection.
Immunocytochemistry
Cells were cultured on coverslips for six days or two days for
pluripotent and differentiated cells respectively. Cells were fixed in
2% formaldehyde, rinsed in PBS, permeabilized with PBS 0.1 %
Triton and incubated with blocking solution (containing 0.3%
BSA, 1x PBS and 5% of normal serum from the specie of the
corresponding secondary antibody) for an hour at room
temperature. The primary antibodies used were anti-hexokinase
II (1:500, Cell Signaling and Technologies). Antibodies were
incubated overnight at 4uC, followed by three washes of 15
minutes in PBS 0.15 Triton. Respective secondary antibodies were
incubated for one hour at 37uC, followed by three washes in PBS
0.1% Triton. Coverslips were assembled in slides using the
fluorescence mounting media Vectashield with DAPI (Vector
Labs, Switzerland). Slides were imaged using a TCS-SP2 laser
scanning confocal microscope (Leica).
Oxygen consumption rates
O2 consumption was determined using Seahorse XF24
extracellular Flux analyzer as previously described by Qian and
Van Houten [37]. Briefly, cells were seeded in the 24-well XF24
cell culture plate in the respective culture media. For pluripotent
cells, matrigel coated plates were used and cells were allowed to
grow for three days, whereas for differentiated cells 300 000 cells
were seeded and allowed to grow for 24 h. Thirty minutes prior to
the run, culture media was replaced by unbuffered DMEM and
plates were incubated at 37uC for 30 minutes for pH and
temperature stabilization. Three mitochondrial inhibitors; oligo-
mycin (1 mM), FCCP (300 mM) and rotenone (1 mM) were
sequentially injected after measurements, 2, 4, and 6, respectively.
After all the measurements were completed, cells were dissociated
and counted.
Statistical analysis
Means and standard error of the mean (SEM) were calculated
and statistically significant differences were determined by One-
way ANOVA followed by Dunnett’s Multiple Comparison test. n
refers to sample size. Statistical significance was determined at
p,0.05. The p values for the Glucose array were calculated using
SABiosciences online software. The test used was a two-tailed
Student’s t-test, and statistical significance was determine at
p,0.05.
Results
Mitochondrial localization and morphology
In order to determine mitochondria morphology and localiza-
tion within the cell in pluripotent versus differentiated cells we
transduced hESCs (WA07 line) and fibroblasts cells (H7TF, IMR-
90 and HFF1) with a baculovirus system containing a leader
sequence for PDH E1 alpha subunit fused with the GFP protein.
Mitochondria in the hESC line WA07 showed perinuclear
localization (Fig. 1A, top left) whereas the mitochondria of their
differentiated counterparts (H7TF) were distributed in the
cytoplasm (Fig. 1A, top right). This might be a consequence of
the high nuclear-cytoplasmic ratio observed in the hESCs.
Furthermore, the mitochondria in the WA07 showed a globular
shape, whereas mitochondria in the H7TF line were mainly
elongated and formed extensive reticular networks. Similarly, the
mitochondria of the somatic lines HFF1 and IMR-90 were also
distributed in the cytoplasm rather than cluster around the
nucleus; their shape was mostly tubular and they formed extensive
networks (Fig. 1A, bottom left and right).
In order to better characterize mitochondrial morphological
features in pluripotent versus differentiated somatic cells we
performed transmission electron microscopy (TEM) for hESCs
(WA07 line), IPSCs (IMR-90 and HFF1 IPSC lines) and
fibroblasts cells (H7TF, IMR-90 lines) (Fig.1B). TEM analysis
demonstrated that mitochondria in hESCs have few cristae and
electron-lucid matrix (Fig. 1B, top left). These results are in
accordance with previous reports [20,21]. TEM of cells obtained
after differentiation of W07 hESCs (H7TF) revealed mitochondria
with an elongated shape, and with a higher number of cristae, as
well as a denser matrix (Fig.1B. bottom, left). Similar to H7TF,
IMR-90 and lung fibroblasts (LF) showed mature mitochondria
with numerous cristae and electron dense matrix (Fig.1B. bottom
center and right, respectively). Interestingly, both IMR-90 and
HFF1 IPSCs showed a mix of both elongated and globular
mitochondria. Furthermore, the matrix of the mitochondria
resembled that of differentiated cells (Fig.1B top, center and right,
respectively). These results suggest that mitochondria morphology
in human IPSCs is not identical to that found in hESCs, but IPSCs
seem to have a mixed phenotype between that found in hESCs
and differentiated cells. It would be of interest to perform
histomorphometric analysis in order to fully validate this
assumption.
Metabolism-related gene expression in human
pluripotent stem cells vs. differentiated cells
To further investigate the metabolic pathways used by human
pluripotent stem cells and differentiated somatic cells we used two
hESC lines (WA07 and WA01), two IPSC lines (IMR-90 IPS and
AE IPS), and two somatic lines (WA07 teratoma fibroblasts-H7TF,
and IMR-90 fibroblasts) and performed the SABiosciences human
glucose metabolism RT2 profiler PCR array. This array contains
84 key genes involved in the regulation of glucose and glycogen
metabolism, along with five housekeeping genes. Overall we
observed that pluripotent lines tend to cluster together rather than
with their somatic counterparts (Fig. 2A, heatmap). Furthermore,
we observed that there are no significant differences in gene
expression between the two hESC lines (WA07 and WA01) used in
this study (Table 1). Statistical analysis showed that when
compared to WA07 cells IMR-90 iPSCs showed 25 genes with
significantly different expression, whereas in AE iPSCs there
were14 such genes (Table 1). For differentiated cells, IMR-90 cells
showed 44 differentially expressed genes whereas for H7TF there
were 18 (Table 1). We further focused our analysis on 60 genes
known to be involved in; glycolysis, pentose phosphate pathway
and TCA cycle (Fig. 2, Table 1). Due to their pleiotropic nature
some of the genes were included in more than one group. In
addition, for the analysis we considered genes that were
differentially expressed at least two fold when compared with the
WA07 line, and with p,0.05.
Regarding the glycolytic signature, six genes among all lines
were either up regulated or down regulated when compared with
the WA07 line (Fig. 2B and Table 1). Among these differentially
expressed genes, ENO 1 and ENO 3 were downregulated (2.02 and
1.98 fold, respectively, p,0.05) in AE IPSC relatively to the
WA07 line, whereas the expression of these did not significantly
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Figure 1. Mitochondrial morphology and localization in human pluripotent stem cells vs. differentiated cells. A) Transduction of
hESCs (WA07 line,) and differentiated cells (H7TF, HFF, and IMR-90 lines) with organelle lights MitoGFP was used investigate mitochondria
morphology and localization within the cell. Blue: DAPI; Green: pyruvate dehydrogenase GFP. Scale bar: 10 mm B) Transmission electron microscopy
(TEM) was used to investigate mitochondria morphologic features in hESCs (WA07 line), IPSCs (HFF1 and IMR-90 IPSC lines), and fibroblasts cells
(H7TF, IMR-90 and HFF1). Scale bar: 500 nm.
doi:10.1371/journal.pone.0020914.g001
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Figure 2. Metabolism-related gene expression in human pluripotent stem cells vs. differentiated cells. A) Heat map of average gene
expression. Gene expression is represented as log10 of Ct values. An increase in gene expression is depicted in red, whereas a decrease in gene
expression is represented by the green color. No differences in expression are depicted in black. Clustering was performed using SABiosciences online
software. The various genes were grouped accordingly to their participation in different metabolic pathways. B) Glycolysis-related genes with at least
two fold difference when compared to the WA07 line. C) Pentose phosphate pathways-related genes with at least two fold differences when
compared to the WA07 line. D) TCA cycle- related genes with at least two fold differences when compared to the WA07 line. Fold changes were
calculated using the -DDCt method relative to the WA07 line. hESC lines are represented in blue, IPSC lines in red and somatic cell lines in green . The
values represent means of three independent experiments. Statistical analysis was performed using Student’s t test (SABiosciences online software)
and significance was determined at p,0.05. Statistically significant differences are represented in Table 1.
doi:10.1371/journal.pone.0020914.g002
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Table 1. p values of fold changes for gene expression.
WA01 AE iPS IMR-90 iPS H7TF IMR-90
Glycolytic signature in human pluripotent stem cells and differentiated cells
GBE1 0.175241 0.182796 0.401636 0.059971 0.003255
GYS1 0.560387 0.305042 0.073519 0.361399 0.006032
UGP2 0.140358 0.583771 0.349007 0.009063 0.00436
AGL 0.716072 0.005425 0.192293 0.003653 0.000895
PGM1 0.118692 0.108458 0.557582 0.443997 0.255193
PGM2 0.314817 0.234121 0.248629 0.699586 0.002456
PGM3 0.219734 0.069024 0.263436 0.527696 0.591157
PYGL 0.12035 0.182944 0.63261 0.469592 0.834941
PYGM 0.105912 0.300795 0.072922 0.163273 0.161997
GSK3A 0.119705 0.144921 0.083618 0.408039 0.061973
GSK3B 0.434825 0.208689 0.086282 0.844473 0.094813
PHKA1 0.117699 0.046949 0.322249 0.283362 0.011132
PHKB 0.759246 0.227841 0.905398 0.490711 0.052339
PHKG1 0.857115 0.004105 0.098563 0.538787 0.712081
PHKG2 0.184464 0.330626 0.305181 0.085937 0.09916
Pentose phosphate signature in human pluripotent stem cells and differentiated cells
G6PD 0.222918 0.12939 0.009571 0.000621 0.000546
H6PD 0.536777 0.772588 0.001435 0.022755 0.005125
PGLS 0.854679 0.021219 0.088223 0.276943 0.975412
PRPS1 0.245115 0.126676 0.019419 0.128065 0.018916
PRPS2 0.831567 0.056076 0.004843 0.465994 0.305017
RBKS 0.119577 0.899118 0.072344 0.913592 0.133126
RPE 0.121207 0.471102 0.264923 0.753951 0.037438
RPIA 0.300618 0.263414 0.010121 0.012123 0.000578
TALDO1 0.61781 0.043175 0.123504 0.065059 0.003374
TKT 0.152685 0.541674 0.001309 0.020472 0.010954
TCA signature in pluripotent stem cells and differentiated cells
ACLY 0.107296 0.234368 0.061387 0.393416 0.246977
ACO1 0.399131 0.079385 0.17169 0.083256 0.001386
ACO2 0.211968 0.089029 0.006734 0.15926 0.006435
CS 0.598438 0.052026 0.45459 0.548219 0.003514
DLAT 0.23882 0.369543 0.531728 0.001807 0.000145
DLD 0.860033 0.027963 0.493081 0.671359 0.004943
DLST 0.628177 0.019154 0.018305 0.726826 0.036226
FH 0.189939 0.945714 0.123065 0.242483 0.105099
IDH1 0.112953 0.38673 0.274658 0.0133 0.009346
IDH2 0.109272 0.7786 0.031926 0.983299 0.759598
IDH3A 0.291665 0.144282 0.699497 0.35153 0.107709
IDH3B 0.126595 0.753791 0.063038 0.271417 0.002515
IDH3G 0.127383 0.888987 0.020491 0.160844 0.22335
MDH1 0.136175 0.888013 0.220693 0.24667 0.032701
MDH1B 0.162897 0.520214 0.113153 0.126206 0.019708
MDH2 0.741719 0.076133 0.030813 0.960944 0.012102
OGDH 0.20949 0.383583 0.033559 0.773533 0.003039
PC 0.10867 0.486329 0.070307 0.698611 0.144088
PCK1 0.606445 0.046384 0.011521 0.331536 0.339268
PCK2 0.10813 0.884791 0.082829 0.167213 0.250898
PDHA1 0.770854 0.041691 0.395379 0.045818 0.00137
PDHB 0.529193 0.012731 0.486834 0.018482 0.000693
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vary for the IMR-90 IPSC line. Instead IMR-90 IPSC displayed
up regulation of BPGM (3.82 fold, p,0.01), and HK2 (3.15 fold,
p,0.05) when compared to the WA07 line (Fig. 2B, Table 1).
Both H7TF and IMR-90 lines showed down regulation of ENO 3
(4.72 fold, p,0.05 and 4.73 fold, p,0.01 for H7TF and IMR-90,
respectively) in comparison with the WA07 (Fig. 2B, Table 1). In
addition, the IMR-90 line showed decreased expression of PGM2
(2.38 fold, p,0.01) and up regulation of ALDO A (2.64 fold,
p,0.001).
In terms of the pentose phosphate pathway seven genes were
differentially expressed among all the lines when compared with
the WA07 line. No differences were observed between the WA07
line and both the WA01 and AE IPSC lines. The IMR-90 IPSC
line showed up regulation of H6PD (4.65 fold, p,0.01), PRPS1
(2.18 fold, p,0.05), PRPS2 (2.17 fold, p,0.01), TKT (2.67 fold,
p,0.01) in comparison with the WA07 line. Both the H7TF and
IMR-90 lines displayed increased expression of G6PD (1.96 fold,
p,0.001 and 2.82 fold, p,0.001, for H7TF and IMR-90,
respectively) H6PD (7.33, p,0.05 and 7.82, p,0.01, respectively),
and decreased expression of TKT (2.13 fold, p,0.05 and 2.65 fold,
p,0.05, respectively) in comparison to the WA07 line. In addition
the IMR-90 line showed decreased expression of PRPS1 (3.96 fold,
p,0.05), RPE (2.50 fold, p,0.05) and RPIA (2.52 fold, p,0.05).
Regarding the TCA cycle signature we observed that 17 genes
were differentially expressed when compared to the WA07 line
(Fig. 2D, Table 1). Again no significant differences were observed
between the two hESC lines. When compared to the WA07 line,
the AE IPSC line displayed decreased expression of DLD (1.98
fold, p,0.05) (Fig. 2C). The IMR-90 IPSC line showed increased
expression of ACO2 (2.09 fold, p,0.01), and SUCLG2 (4.08 fold,
p,0.05) when compared with the WA07 line (Fig. 2C). Both the
H7TF and IMR-90 lines showed down regulation of DLAT (2.65
fold, p,0.01 and 4.65, p,0.001, for H7TF and IMR-90,
respectively) and IDH1 (6.34 fold, p,0.05 and 14.13 fold,
p,0.01) for H7TF and IMR-90, respectively) when compared
with the WA07 line (Fig. 2C, Table 1). In addition, the IMR-90
line demonstrated decreased expression of CS (2.21 fold, p,0.01),
DLD (4.65 fold, p,0.001), DLST (2.22 fold, p,0.05), IDH3B (3.44
fold, p,0.01), MDH1 (3.43 fold, p,0.05), MDH1B (6.52 fold,
p,0.05), PDHA1 (2.78 fold, p,0.01), PDHB (2.88, p,0.001),
SDHC (1.96, p,0.01) and SUCLA2 (2.52, p,0.05), and up
regulation of ACO 1 (2.13 fold, p,0.01).
With respect to genes involved in the regulation of TCA cycle
activity two genes were differentially expressed among all lines and
the WA07 line (Table 1). No significantly expressed genes were
detected between WA07 line, and the WA01, AE IPSC and IMR-
90 IPSC lines. Both differentiated lines showed down regulation of
PDP2 (3.52 fold, p,0.05 and 4.55 fold, p,0.01 for H7TF and
IMR-90, respectively). In addition the IMR-90 displayed de-
creased expression of PDK3 (5.32 fold, p,0.01).
Mitochondrial contribution to the energy metabolism of
human pluripotent stem cells and differentiated cells
To further understand mitochondrial contribution to the energy
metabolism of pluripotent cells we analyzed protein expression of
mitochondrial complexes II, III and V in pluripotent vs.
differentiated somatic cells. We observed no statistical significant
differences in mitochondrial complexes II, III and V between the
various pluripotent lines. Intriguingly, we observed that pluripo-
tent cells have higher protein levels of mitochondrial complexes,
II, III and V than differentiated cells (Fig. 3A, B). Indeed, when
compared to the WA07 line, mitochondrial complex V protein
levels were decreased by 45% and 46% in IMR-90 and HFF1
fibroblasts, respectively (p,0.01 Fig. 3A,B). Furthermore, complex
III protein levels were decreased by 76.8%, 38% and 27% in
IMR-90, HFF1 and H7TF fibroblasts, respectively (p,0.01,
Fig. 3A,B). Although, we observed a decreased expression trend
for mitochondrial complex II in differentiated cells, there was not
statistical significance.
In order to determine if the differences observed in mitochon-
drial complex expression could be translated in terms of higher
mitochondrial activity in pluripotent cells we determine O2
consumption rate (OCR) using the Seahorse XF24 extracellular
flux analyzer. We have used a pharmacological profiling
approach, by combining the use of three mitochondrial inhibitors
(rotenone, FCCP and oligomycin) and the Seahorse instrument as
previously described by Qian and Van Houten [37]. The OCR
response to the chemical compounds were analyzed in one hESC
line (WA01), one IPSC line (AE) and two differentiated cell lines
(H7TF and IMR-90).
The basal OCR (measure of OXPHOS) is the amount oxygen
consumption that is linked to ATP synthesis in the mitochondria,
and represents the mean basal levels of oxygen consumption minus
the mean of the two values following oligomycin treatment
(measurements 3 and 4). Oligomycin inhibits ATP synthase by
binding to the oligomycin sensitivity-conferring protein (OSCP) at
the F0 subunit of the ATP synthase. This binding blocks the proton
conductance resulting in loss of electron transfer and O2
consumption. Addition of oligomycin resulted in decreased levels
of OCR in all cell types (Fig. 3C). Nonetheless the kinetics and
relative intensity of response varied among the various cell types
WA01 AE iPS IMR-90 iPS H7TF IMR-90
SDHA 0.518039 0.053203 0.04001 0.445353 0.210469
SDHB 0.835404 0.151871 0.250403 0.557484 0.01685
SDHC 0.232507 0.009183 0.168632 0.033296 0.002187
SDHD 0.415562 0.059517 0.463437 0.475622 0.011049
SUCLA2 0.340556 0.193395 0.129939 0.172629 0.014183
SUCLG1 0.328695 0.025023 0.153357 0.198642 0.045376
SUCLG2 0.106127 0.465278 0.01718 0.621296 0.237038
Glycolysis; Pentose phosphate and TCA-related genes p values. p values of fold change were determined relative to the WA07 line. Statistical significance was
determined at p,0.05 by Student’s t test (SABiosciences online software). p values represented in red correspond to genes that are significantly up regulated, whereas
p values depicted in green represent genes that are significantly down regulated. p values above 0.05 are represented in black.
doi:10.1371/journal.pone.0020914.t001
Table 1. cont.
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Figure 3. Mitochondrial contribution to the energetic metabolism of human pluripotent stem cells and differentiated cells. A)
Western blotting analysis of mitochondrial complexes II, III and V. b-actin was used as a loading control. B) Quantification of mitochondrial complexes
II, III and V protein levels relative to the WA07 line. C) Oxygen consumption rate (OCR) was determined by Seahorse XF24 analyzer. The three
mitochondrial inhibitors were sequentially injected (after measurement points, 2, 4, and 6, as indicated) and the final concentrations of each were:
oligomycin (1 mM); FCCP (300mM); rotenone (1 mM) D) Basal OCR (represents the mean of the first two measurements minus the mean of
measurements 3 & 4). E) Reserve capacity (FCCP induced levels, measurements 5 & 6 minus the basal level). F) Intracellular ATP levels determined by
HPLC. G) Lactate levels secreted to the media. The values are averages of three independent experiments. Statistical significance was determined by
one-way ANOVA followed by Dunnet’s multiple comparison test. Statistical significance was determined at P,0.05. Error bars: SEM.
doi:10.1371/journal.pone.0020914.g003
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with hESCs having the slowest and less pronounced response
followed by IMR-90, AE IPSC and finally H7TF (Fig.3C).
The H7TF cells showed higher basal O2 consumption rates
when compared to the other cell types (Fig. 4C and 4E). The
lowest basal OCR was observed for hESCs (WA01) and the
differentiated line IMR-90 (Fig. 4C and 4E). The AE IPSC line
displayed intermediate basal OCR levels between those found for
the H7TF and WA01 line (Fig. 4C and 4D). Likewise to what was
observed in glucose-related gene expression there were marked
differences between the IMR-90 and H7TF with respect to their
basal OCR. Because H7TF cells are derived from teratomas one
could question whether the OCR levels of these cells are
representative of other differentiated lines. In order to address
that question we performed OCR measurements for a normal
diploid human skin fibroblast line (NDHF). We observed that
OCR levels in these cells are similar to those observed in H7TF
rather to those observed in the IMR-90 cells (Fig.S1).
FCCP is a mitochondrial uncoupler that dissipates the proton
gradient, and therefore uncouples electron transport and mito-
chondrial respiration from ATP synthesis. FCCP treatment has
been shown to increase O2 consumption to its maximum in
various cell types. In fact FCCP resulted in an increase of OCR
levels in all cell types, with the most pronounced response being
observed in H7TF, followed by IMR-90, AE IPS and WA01 cells
(Fig. 3C). The difference between FCCP OCR and basal OCR is
a good measure of respiratory capacity (also designed of reserve
capacity) of these cells. Indeed we observed that the respiratory
capacity of differentiated cells is higher than that observed for
pluripotent lines (Fig.3E).
Rotenone is a mitochondrial inhibitor that prevents electron
transfer from complex I to ubiquinone by blocking the ubiquinone
binding site [38]. Treatment with rotenone decreased OCR levels
in all cells types although H7TF fibroblasts showed a more
pronounced response to the treatment. Overall our results suggest
that both hESCs and IPSCs have lower reliance in OXPHOS
when compared to the H7TF cells. Interestingly IMR-90
fibroblasts showed low basal O2 consumption rates, but when
challenged with FCCP had the ability to increase OXPHOS rates
to a similar extent to that observed in other differentiated cell types
(H7TF and NDHF). In contrast both hESCs and IPSCs showed a
considerably reduced response to FCCP than differentiated cells
(H7TF and NDHF). These results suggest that mitochondria in
pluripotent cells, although functional, present a low activity rate,
and that the differences in mitochondrial content noted previously
do not directly account for differences in activity. Indeed we
observed that mitochondria membrane potential is lower in
hESCs when compared to their differentiated counterparts (data
not shown).
Total ATP levels are originated both from anaerobic and aerobic
respiration. In order to determine intracellular ATP levels in human
pluripotent stem cells and differentiated cells we performed HPLC
(Fig. 3F). Our results showed that somatic cells have elevated
intracellular ATP levels when compared to differentiated cells. In
addition we measure lactate secretion to media (a good measure for
glycolysis that does not add to the TCA cycle) in human pluripotent
stem cells and differentiated cells (Fig.3G). As expected human
pluripotent cells displayed higher lactate levels than differentiated
cells. Overall these results suggest that human pluripotent stem cells
rely mostly on glycolysis to meet their energy demands.
Hexokinase II expression in human pluripotent stem cells
and differentiated cells
Mammalian tissues harbor four hexokinases isoforms (I–IV) with
particular kinetics and tissue specificity. Both hexokinase I and II
have an N-terminal hydrophobic domain that allows binding to the
outer mitochondrial membrane. Pedersen and colleagues have
shown that mitochondrial-bound hexokinase II is responsible for the
high glycolytic profile of rat hepatoma cells [26,27]. In order to
determine if hexokinase II could play a role in the maintenance of
high glycolytic rates in pluripotent cells we performed western
blotting analysis for hexokinase II in three hESC lines (WA01,
WA07 and WA09), three IPSC lines (IMR-90 IPSC, AE IPS and
HFF1 IPSC) three differentiated lines (H7TF, IMR-90 and HFF1).
We observed that pluripotent cells overexpress hexokinase II when
compared to differentiated cells (Fig 4A, B). We next isolated the
cytoplasmic and mitochondrial fractions of hESCs (WA01 line),
IPSCs (AE IPS and IMR-90 IPS) and fibroblasts cells (H7TF and
IMR-90) and determined hexokinase protein levels in both fractions
(Fig. 4C, D, respectively). We observed that hexokinase II in
differentiated cells is preferentially localized in the cytoplasm,
whereas pluripotent cells display high levels of hexokinase II in both
cytoplasmic and mitochondrial fractions. Binding of hexokinase II
to the outer mitochondrial membrane can enhance mitochondrial
metabolism in two ways; first when bound to the outer
mitochondrial membrane, hexokinase escapes the inhibitory effect
of its product glucose 6-phosphate; second mitochondrial binding
allows hexokinase II to gain access to ATP that permeates the
voltage dependent anion channel [39,40].
PDH complex regulation in human pluripotent stem cells
and differentiated cells
Key metabolic regulation in terms of glycolysis versus
OXPHOS involves the PDH complex. We therefore analyzed
PDHK1, phospho PDH and total PDH protein in pluripotent
stem cells and differentiated cells. We observed that PDHK1
protein levels are up regulated in pluripotent cells when compared
to differentiated cells (Fig.5 A, B). Statistical analysis revealed that
there are no significant differences between the WA07 hESC line
and the other pluripotent lines (Fig. 5B). Although, there was a
decrease in PDHK1protein levels between the WA07 line and
both H7TF and HFF1 fibroblast lines (49% and 34% decrease for
H7TF and HFF1, respectively; p,0.05) no significant differences
were observed for the IMR-90 line (Fig. 5B). Interestingly, we did
not observe an increase in PDK1 gene expression in pluripotent vs.
differentiated cells (Fig. S2 and Table S1). This result suggests that
PDHK1 protein stabilization differs between pluripotent and
differentiated cells. Consistent with higher PDHK1 protein levels,
pluripotent cells also displayed higher phospho PDH levels when
compared to differentiated cells (Fig.5 A and C). All three
differentiated lines showed lower phospho PDH protein when
compared with the hESC line WA07 ( 44%, 64% and 39%
decrease for H7TF, IMR-90 and HFF1 fibroblast, respectively;
p,0.01; Fig. 5C). Interestingly, both AE and IMR-90 IPSCs
showed lower levels of phospho-PDH than the WA07 line (20%
and 26% decrease for AE IPSCs and IMR-90 IPSCs, respectively;
p,0.01; Fig. 5C). No significant differences were found for total
PDH levels. These results suggest that the lower mitochondrial
activity observed in pluripotent cells might, at least partially, be
attributed to high levels of phospho PDH. Our results further
suggest that besides PDHK1 other PDHKs are regulating the
activity of the PDH complex in these cells, as no significant
differences were observed for the PDHK levels in IMR-90 cells but
these cells displayed higher levels of phospho PDH.
Discussion
In this study we sought to understand the energetic metabolism
of pluripotent stem cells and their differentiated counterparts. We
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Figure 4. Hexokinase II expression in human pluripotent stem cells and differentiated cells. A)Western blotting analysis for hexokinase II
protein levels. B) Quantification of Hexokinase II protein levels relative to the WA07 line. C–E) Hexokinase II protein levels in the cytoplasmic and
mitochondrial fractions, respectively. b-actin was used as a loading control. Values are means of three independent experiments. Statistical
significance was determined at p,0.05 by one-way ANOVA followed by Dunnet’s multiple comparison test. Error bars: SEM
doi:10.1371/journal.pone.0020914.g004
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started by looking at mitochondrial morphology and localization
in human pluripotent stem cells (both hESCs and IPSCs), and
somatic cells. In agreement with previous reports our results
demonstrate that mitochondria in hESCs appear immature with
fewer cristae, and low electron density matrix, when compared to
differentiated somatic cells [16,20]. Interestingly IPSCs displayed a
mixed mitochondrial phenotype that still resembles the somatic
cells of origin and is not quite that of ESCs.. Analyzing distinct
mitochondrial features during the reprogramming process and
how they compare with the acquisition and stabilization of
pluripotency characteristics would therefore be of interest, and
might provide novel insights into mitochondrial activity and
metabolic shifts during reprogramming.
Glucose-related gene expression analysis revealed that both
hESC lines analyzed in this study have identical glucose-related
metabolism signatures. In contrast IPSCs are not identical to
hESCs, although they cluster together, rather than with their
somatic counterparts. Interestingly both IPSC lines analyzed in
this study showed different metabolic gene expression signatures,
with IMR-90 IPSCs having higher transcripts levels. It should be
noted that that the cocktail of transcription factors used for the
reprogramming of both lines differ [1]. However recent papers
[10] established a genome-wide map for DNA methylation and
gene expression for a considerable number of IPSC lines
generated using several somatic cells and various methodologies,
demonstrating some cell-line differences in gene expression that
are probably not due to a single factor. It would be interesting to
determine if these differences are also reflected in terms of
functional metabolic studies.
Regarding the glycolytic signature of human pluripotent stem
cells and somatic cells we observed that H7TF fibroblasts
displayed similar glycolytic signature to their pluripotent counter-
part the WA07 hESC line, with only four genes significantly
downregulated. Interestingly the IMR-90 fibroblasts displayed 10
genes differentially expressed (six genes significantly downregulat-
ed and four genes up regulated when compared to the WA07).
Cell division requires not only ATP but biosynthetic precursors
derived from glycolysis, the pentose phosphate pathway and the
TCA cycle. For instance, glucose 6-phosphate can be diverted
from the glycolytic pathway to the pentose phosphate pathway in
order to generate ribose 5-phophate for de novo nucleotide
synthesis. The pentose phosphate pathway can be divided in two
major branches, an oxidative branch and a non-oxidative branch
[41]. Our gene expression analysis demonstrated that both G6PD
and H6PD are significantly up regulated in differentiated cells. The
enzymes encoded by these genes catalyze the first step in the
oxidative branch of the pentose phosphate pathway that involves
the conversion of glucose 6-phosphate to 6-phosphogluconate with
Figure 5. Pyruvate dehydrogenase regulation in human pluripotent stem cells and differentiated cells. A) Western blotting analysis of
PDHK1, pPDH and total PDH protein levels. b-actin was used as a loading control. B–D) Protein levels quantification relative to the Wa07 line of
PDHK1, pPDH and PDH, respectively. Values are means of three independent experiments. Statistical significance was determined at p,0.05 by one-
way ANOVA followed by Dunnet’s multiple comparison test. Error bars: SEM Abbreviations: PDHK1, pyruvate dehydrogenase kinase one; pPDH:
phospho Ser 293 pyruvate dehydrogenase subunit E1a; PDH: pyruvate dehydrogenase.
doi:10.1371/journal.pone.0020914.g005
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concomitant production of NADPH. Besides its role as a cofactor
in many biosynthetic reactions, NADPH is essential to regenerate
reduced glutathione from glutathione disulfide [42]. Hence G6PD
and H6PD transcripts levels may reflect high requirement for
NADPH, either as reducing agent for biosynthetic pathways or
instead as a cofactor in the cell antioxidant defense. The latter
hypothesis is supported by the fact that differentiated cells have a
higher mitochondrial activity and therefore a higher potential for
ROS production. Furthermore, we observed that human plurip-
otent cells have higher expression levels of genes related to the
non-oxidative branch, such as TKT, and RPIA. These results
suggest that human pluripotent cells preferentially use the non-
oxidative branch of the pentose phosphate pathway in order to
obtain ribose-5 phosphate which is important for nucleotide
synthesis. A similar pattern has been previously described for
cancer cells [43,44,45].
Interestingly, the TCA cycle signature revealed that most of
these genes are downregulated in differentiated cells, when
compared to pluripotent lines. Besides its role in oxidative
catabolism of carbohydrates and fatty acids, the TCA cycle
provides precursors for many biosynthetic pathways, including
precursors for amino acid and nucleotide synthesis. It is possible
that up regulation of TCA cycle-related genes in human
pluripotent stem cells is related to the high proliferative rates
and concomitant need for nucleotides rather than need for
reducing agents for mitochondrial activity. This issue needs to be
explored further. Regardless, higher levels of genes encoding TCA
cycle proteins might be indicative of increased electron transport
capacity and cellular respiration. Consistent with increased level of
genes encoding proteins of the TCA cycle we observed that
pluripotent lines have higher levels of mitochondrial electron
transport complexes than differentiated cells. The transcription
factor c-Myc is crucial for the maintenance of embryonic stem cell
self-renewal and its ectopic expression allows the reprogramming
of somatic cells to an embryonic stem cell like state [1,3]. In
addition this transcription factor has been previously described to
up regulate the expression of several glycolytic enzymes as well as
to promote mitochondrial biogenesis [46,47,48,49]. Hence higher
levels of complex II, III and V may be due to higher c-myc levels
in pluripotent cells and may not be representative of high
mitochondrial activity. In accordance with this hypothesis our
OCR results showed that pluripotent lines consume lower levels of
O2 than the differentiated line H7TF. However, IMR-90
fibroblasts displayed similar basal OCR levels than those found
in pluripotent lines. These results could be related to the fetal
origin of the IMR-90 fibroblasts, as the fetal lung is exposed to a
rather hypoxic environment [50]. In agreement with this notion,
when we induced mitochondrial respiration by the use of FCCP
(reserve capacity) IMR-90 fibroblasts could increase OCR to
similar levels to those found in H7TF. Importantly, human
pluripotent stem cells did not display a strong response to FCCP
treatment suggesting that aerobic respiration in these cells is
somewhat impaired. Consistent with less active mitochondria,
human pluripotent cells showed reduced ATP levels when
compared with differentiated cells. In addition these cells secreted
higher lactate levels indicative of higher glycolytic rates. Thus
despite higher levels of genes encoding proteins from the TCA
cycle and higher content in mitochondrial electron transport chain
complexes, human pluripotent cells seem to have lower overall
OXPHOS activity. It remains to be established why this is the
case, but our data suggests some possibilities.
Hexokinase II catalyzes the first reaction of glycolysis and it has
been previously demonstrated that its expression is restricted to the
inner cell mass of the blastocyst, and that HK2 knock down results
in mouse embryonic lethality around E.D. 7.5 [51,52]. Although
we did not observe significant differences at mRNA level, the total
protein levels of hexokinase II were significantly elevated in human
pluripotent stem cells. These results suggest that hexokinase II
protein stabilization might be increased in human pluripotent
lines. Higher levels of mitochondrial hexokinase II can be
advantageous for glycolytic metabolism in two ways: first binding
of hexokinase II the outer mitochondrial membrane allows this
enzyme to escape inhibition by its product glucose-phosphate; and
second it allows the enzyme to gain access to newly synthesized
ATP required for the phosphorylation of glucose [39,40]. In
addition, hexokinase II plays a key role in the prevention of cell
death by binding to VDAC, therefore representing a link between
glucose metabolism and apoptosis [53,54]. Hence it is possible that
hexokinase II plays a role in preventing human pluripotent stem
cell apoptosis as well.
On the other hand, the PDH complex is a crucial step in regulation
of metabolism since it constitutes the link between anaerobic
metabolism and the TCA cycle. Phosphorylation of the PDH E1a
subunit leads to inactivation of the PDH complex and consequently
results in lower levels of acetyl CoA to enter the TCA cycle. Tellingly,
pluripotent lines have higher levels of phosphorylated PDH E1a.
Phosphorylation of PDH complex can be carried out by four PDHKs
and in this study we analyzed PDHK1 expression levels. Although we
did not observe an increase in PDHK1 gene expression in pluripotent
lines when compared to differentiated cells we did observe an increase
in PDHK1 protein levels in pluripotent cells. These results suggest that
PDHK1 protein stability differs between pluripotent and differenti-
ated cells. Papandreou and colleagues have previously demonstrated
that under hypoxic conditions hypoxia inducible factor (HIF-1) up
regulation resulted in increased expression of PDHK1 leading to
inactivation of the PDH complex. This in turn resulted in reduced
substrate availability to enter the TCA cycle and led to decreased
oxidative phosphorylation [55]. HIF-1a might therefore be considered
a good target for future work, given that we observed that some of its
targets are involved in the maintenance of this glycolytic profile.
Overall our results demonstrate that human pluripotent cells
have a greater reliance on glycolysis than differentiated cells. In
addition our study suggests that this can be mediated by increasing
hexokinase II levels and inactivation of the PDH complex.
Interestingly these metabolic strategies involving features of
anaerobic metabolism under normoxia are also found in many
types of tumor cells [34,56], and parallel assays in both pluripotent
and tumor lines would be extremely interesting Importantly we
demonstrate that despite the fact that both hESCs and IPSCs rely
on glycolysis, these cell types are not identical in terms of glucose-
related gene expression, mitochondrial morphology, and O2
consumption. This suggests that IPSC somatic cell reprogramming
to IPSC may result in differences at the metabolic level, when
compared to the pluripotent standard of hESC. While epigenetic
and transcriptomic differences have been mentioned above [9,10]
other significant genetic changes in IPSCs when compared to
hESCs and differentiated cells were also recently described
[11,12], including higher mutation rates and copy number
variation. Interestingly, recent data suggests that IPSCmitochon-
dria retain significant developmental plasticity upon IPSC
generation, and somatic cell re-differentiation. [57].
In addition we also observe that not all the differentiated lines
display the same metabolic profile and this might have an impact
in the reprogramming efficiency of various somatic cell types, and
on the characteristics of differentiated cells obtained from different
IPSC lines. These results stress the importance of the complete
characterization of these cell lines, and suggest that there may be
other links to tumor cells besides those already described.
Energy Metabolism in Pluripotent Cells
PLoS ONE | www.plosone.org 13 June 2011 | Volume 6 | Issue 6 | e20914
Supporting Information
Figure S1 Comparison of OCR in two differentiated cell
lines. A) Oxygen consumption rate (OCR) was determined by
Seahorse XF24 analyzer for IMR-90 and NHDF lines, the former
also listed in Figure 3. The mitochondrial inhibitors were
sequentially injected at specific time points as illustrated in the
figure. B) Basal OCR (represents the mean of the first three
measurements minus the mean of measurements 4, 5 & 6). E)
Reserve capacity (FCCP induced levels, measurements 7, 8 & 9
minus the basal level). Measurements show that NHDF cells show
higher values than IMR-90 cells, similarly to what is described for
the other differentiated cell line (H7TF) listed in Figure 3
(TIF)
Figure S2 p-values for the glucose metabolism gene
expression array in human pluripotent stem cells vs.
differentiated cells. Statistical analysis was performed using
SABiosciences online software and Student’s t test was applied.
Significance was determined at p,0.05.
(PDF)
Table S1 Average Ct values for gene expression.
Differences were calculated using the -DDCt method and gene
expression was normalized to the housekeeping gene b-actin.
Average Ct values were determined using online software provided
by SABiosciences.
(PDF)
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